CYPHERPUNK TECHNOLOGIES INC. 8K

Cypherpunk Technologies reported Q1 2026 results showing a large unrealized loss on its expanded Zcash treasury, a new $5 million investment in ZODL, and key oncology milestones at its Leap Therapeutics subsidiary, including FDA Fast Track designation and positive Phase 2 data for sirexatamab.

On May 14, 2026, Cypherpunk Technologies Inc. reported its unaudited financial results for the quarter ended March 31, 2026, highlighting a sharp increase in net loss to $77.2 million from $15.4 million a year earlier, primarily due to a $77.6 million unrealized loss on its Zcash (ZEC) digital asset treasury as the ZEC price fell from $508.09 to $240.47 during the quarter. The company disclosed that it had increased its ZEC holdings to 314,185.70 ZEC (about 1.88% of circulating supply) at an average cost of $337.86 per ZEC, including purchases of 10,279.30 ZEC for $5 million between April 15 and May 13, 2026, and reported cash and cash equivalents of $6.7 million and ZEC holdings valued at $73.8 million as of March 31, 2026. Cypherpunk also announced a $5 million strategic investment in Zcash Open Development Labs (ZODL), its first privacy-technology investment outside of ZEC itself, and launched a new corporate website and investor dashboard. Its Leap Therapeutics subsidiary reported significant operational milestones, including U.S. FDA Fast Track designation in May 2026 for sirexatamab in combination regimens for DKK1-high metastatic colorectal cancer after one prior systemic therapy, and positive Phase 2 DeFianCe study data presented at AACR 2026 showing statistically significant improvements in overall response rate and overall survival in DKK1-high colorectal cancer patients using a new plasma DKK1 biomarker assay. Operating expenses fell markedly on lower R&D spending following completion of clinical trials, while general and administrative expenses rose due to higher stock-based compensation, and the company emphasized both the risks and strategic rationale of its ZEC-focused treasury and ongoing oncology development programs in detailed forward-looking statements.

Filing Facts

CIK

1509745

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-060686

Alert Tier

7